Spots Global Cancer Trial Database for Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
Official Title: Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
Study ID: NCT05206942
Conditions
Study Description
Brief Summary: Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford, Palo Alto, California, United States
Contact Details
Name: Alice C. Fan, MD
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Name: Jeremy Dahl, Ph.D
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Name: Aya Kamaya, M.D
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
